About Molly Harper
Molly Harper is a director at PreciseDx.
Molly Harper first appears on SEC filings in 2024.
Experience
This experience comes from Molly Harper's profile and from SEC filings. For roles taken from filings, the years are when the filings name Molly Harper in the role, so the role may have started earlier or lasted longer.
NC
New York Blood Center Current
Entrepreneur in Residence
2025 – Present
PH
Peacock Hall Current
Managing Partner
2024 – Present
PreciseDx, Inc. Current
Board of Directors, Independent Director
2021 – Present · New York, NY
Breast cancer recurrence risk assessments for clinical care teams.
CI
Catalyst Pharmaceuticals, Inc.
Board of Directors, Lead Independent Director
2021 – 2026
SI
Synlogic, Inc.
Chief Strategy & Business Officer
2021 – 2024
RI
Relmada Therapeutics, Inc
Executive Vice President, Operations
2020 – 2021
AT
Akcea Therapeutics
SVP & GM - Cardiometabolic & Transthyretin Amyloidosis Franchises
2015 – 2019
SA
Sanofi
Head & General Manager, US Endocrinology, Rare Disease Division/Genzyme
2014 – 2015
GE
Genzyme
Senior Director, US Marketing, Endo-Cardio Business Unit
2009 – 2014
ME
Merck
New Product Planning, Analytics, Market Research, Brand Marketing, Primary Care Sales
2004 – 2009
JJ
Johnson & Johnson
Johnson & Johnson Development Corp (JJDC), Venture Capital
2003
UB
UBS
Equity Research - Life Sciences
2000 – 2002
TI
The Wilkerson Group/IBM
Strategy Consulting
1998 – 1999
Key Colleagues at Startups
The people Molly Harper works with at each company, as listed on that company's latest Form D.
PreciseDx, Inc. · Form D, Oct 7, 2026
Eric Converse
Chief Executive Officer and director
Paul Roma
Chairman
WD
Westley Dupray
Director
EL
Erik Lium
Director
MJ
Michael Hennessy Jr.
Director
ES
Edward Sitar
Chief Financial Officer